Here’s whether Akebia Therapeutics, Inc. (AKBA) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Caution.
🟡
Caution
Positives: above the 50-day MA (medium-term momentum positive); RSI 54 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); weak 1-year return of -26.1%. Currently 65.5% off its 52-week high. Score: -1/7.
AKBA is trading below its 200-day MA ($2.22) — a key warning sign the longer-term trend is under pressure. An RSI of 54.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -26.1% compares to +35.1% for SPY (trailed the market by 61.1%). The current 65.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.
$10,000 invested 1 year ago→ $7,395 today
vs. S&P 500 (SPY) — same period trailed market by 61.1%